Based on the low proportion of T cells, especially CD4+ T, and the even further decline of this subtype with tumor progression, we can assume that the source of these cytokines are myeloid cells and ILCs present in the tumor microenvironment, as the ILC3 population and IL-22 expression increased at the same time. This evidence concerns the gene IL22 and neoplasm.